{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:35:30Z","timestamp":1782815730021,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1124\/dmd.111.041095","type":"journal-article","created":{"date-parts":[[2011,11,24]],"date-time":"2011-11-24T06:01:14Z","timestamp":1322114474000},"page":"450-460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Molecular Mechanism of Altered Ezetimibe Disposition in Nonalcoholic Steatohepatitis"],"prefix":"10.1016","volume":"40","author":[{"given":"Rhiannon N.","family":"Hardwick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig D.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Street","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Canet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J.","family":"Cherrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.111.041095_bib1","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1464-5491.2005.01748.x","article-title":"Recent concepts in non-alcoholic fatty liver disease","volume":"22","author":"Adams","year":"2005","journal-title":"Diabetic Med"},{"key":"10.1124\/dmd.111.041095_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/07853890802552437","article-title":"New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)","volume":"41","author":"Ali","year":"2009","journal-title":"Ann Med"},{"key":"10.1124\/dmd.111.041095_bib3","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1124\/dmd.30.7.838","article-title":"Tissue distribution and chemical induction of multiple drug resistance genes in rats","volume":"30","author":"Brady","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.041095_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1124\/jpet.300.1.97","article-title":"Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats","volume":"300","author":"Cherrington","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.041095_bib5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1124\/jpet.103.062091","article-title":"Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3","volume":"309","author":"Chu","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.041095_bib6","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.108.026146","article-title":"Complex pharmacokinetic behavior of ezetimibe depends on Abcc2, Abcc3, and Abcg2","volume":"37","author":"de Waart","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.041095_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1751-2980.2008.00323.x","article-title":"Impact of non-alcoholic fatty liver disease on accelerated metabolic complications","volume":"9","author":"Fan","year":"2008","journal-title":"J Dig Dis"},{"key":"10.1124\/dmd.111.041095_bib8","first-page":"233","article-title":"Commonly used animal models of non-alcoholic steatohepatitis","volume":"8","author":"Fan","year":"2009","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1124\/dmd.111.041095_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2009.04.002","article-title":"Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats","volume":"613","author":"Fisher","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.111.041095_bib10","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.041095_bib11","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.0500269102","article-title":"The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1)","volume":"102","author":"Garcia-Calvo","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.111.041095_bib12","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1124\/dmd.110.035006","article-title":"Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease","volume":"38","author":"Hardwick","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.041095_bib13","series-title":"Guide for the Care and Use of Laboratory Animals","year":"1996"},{"key":"10.1124\/dmd.111.041095_bib14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"4","author":"Kosoglou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.111.041095_bib15","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1124\/dmd.107.015107","article-title":"Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease","volume":"35","author":"Lickteig","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.041095_bib16","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/hep.20898","article-title":"Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene","volume":"42","author":"Manautou","year":"2005","journal-title":"Hepatology"},{"key":"10.1124\/dmd.111.041095_bib17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini","year":"2003","journal-title":"Hepatology"},{"key":"10.1124\/dmd.111.041095_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmed.2007.12.003","article-title":"Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis","volume":"14","author":"Marra","year":"2008","journal-title":"Trends Mol Med"},{"key":"10.1124\/dmd.111.041095_bib19","first-page":"S17","article-title":"Pathophysiology of nonalcoholic steatohepatitis","volume":"40","author":"McCullough","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"10.1124\/dmd.111.041095_bib20","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1053\/jhep.2002.33327","article-title":"Altered localization and activity of canalicular Mrp2 in estradiol-17\u03b2-d-glucuronide-induced cholestasis","volume":"35","author":"Mottino","year":"2002","journal-title":"Hepatology"},{"key":"10.1124\/dmd.111.041095_bib21","doi-asserted-by":"crossref","first-page":"G327","DOI":"10.1152\/ajpgi.00227.2004","article-title":"Role of microtubules in estradiol-17\u03b2-d-glucuronide-induced alteration of canalicular Mrp2 localization and activity","volume":"288","author":"Mottino","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/dmd.111.041095_bib22","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1002\/jps.20996","article-title":"Disposition of the cholesterol absorption inhibitor ezetimibe in mdr1a\/b (\u2212\/\u2212) mice","volume":"96","author":"Oswald","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.111.041095_bib23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/jps.21821","article-title":"Synergistic influence of Abcb1 and Abcc2 on disposition and sterol lowering effects of ezetimibe in rats","volume":"99","author":"Oswald","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.111.041095_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jchromb.2005.10.034","article-title":"A LC-MS\/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1","volume":"830","author":"Oswald","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.111.041095_bib25","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1124\/jpet.106.104018","article-title":"Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats","volume":"318","author":"Oswald","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.041095_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000282097","article-title":"Animal models of non-alcoholic steatohepatitis: of mice and man","volume":"28","author":"Schattenberg","year":"2010","journal-title":"Dig Dis"},{"key":"10.1124\/dmd.111.041095_bib27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/dmd.30.3.240","article-title":"Increase in rat liver UDP-glucuronosyltransferase mRNA by microsomal enzyme inducers that enhance thyroid hormone glucuronidation","volume":"30","author":"Vansell","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.041095_bib28","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1124\/mol.104.004481","article-title":"Role of glycosylation in trafficking of Mrp2 in sandwich-cultured rat hepatocytes","volume":"67","author":"Zhang","year":"2005","journal-title":"Mol Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624226386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624226386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.111.041095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T20:06:27Z","timestamp":1739909187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624226386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0090955624226386"],"URL":"https:\/\/doi.org\/10.1124\/dmd.111.041095","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Mechanism of Altered Ezetimibe Disposition in Nonalcoholic Steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.111.041095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}